Tanvex BioPharma, Inc. (6541.TW)
- Previous Close
58.20 - Open
57.10 - Bid 57.50 x --
- Ask 57.70 x --
- Day's Range
57.10 - 58.50 - 52 Week Range
35.05 - 82.00 - Volume
51,792 - Avg. Volume
404,894 - Market Cap (intraday)
9.45B - Beta (5Y Monthly) 0.03
- PE Ratio (TTM)
-- - EPS (TTM)
-9.20 - Earnings Date Aug 7, 2025 - Aug 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
www.tanvex.comRecent News: 6541.TW
View MorePerformance Overview: 6541.TW
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6541.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6541.TW
View MoreValuation Measures
Market Cap
9.84B
Enterprise Value
11.12B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
268.60
Price/Book (mrq)
11.02
Enterprise Value/Revenue
320.54
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.84%
Return on Equity (ttm)
-161.17%
Revenue (ttm)
34.68M
Net Income Avi to Common (ttm)
-1.38B
Diluted EPS (ttm)
-9.20
Balance Sheet and Cash Flow
Total Cash (mrq)
376.96M
Total Debt/Equity (mrq)
184.51%
Levered Free Cash Flow (ttm)
-792.54M